← Ireland

S.I. No. 229/2025 - Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2025

S.I. No. 229/2025 - Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2025 Skip to content Disclaimer Feedback Helpdesk Gaeilge Léim go dtí an t-ábhar Séanadh Aiseolas Deasc chabhrach English Gaeilge English Produced by the Office of the Attorney General Táirgthe ag Oifig an Ard-Aighne Home Legislation Acts of the Oireachtas Statutory Instruments Pre-1922 Legislation Constitution External Resources Bills (Houses of the Oireachtas) Iris Oifigiúil / Official Gazette Revised Acts (LRC) Classified List of Legislation (LRC) Translations (acts.

  1. ie)Translations (Houses of the Oireachtas) Government Publications for Sale EU Law (EUR-Lex) FAQ Disclaimer Feedback Helpdesk Search Baile Reachtaíocht Achtanna an Oireachtais Ionstraimí Reachtúla Reachtaíocht Réamh-1922 Bunreacht Acmhainní Seachtracha Billí (Tithe an Oireachtais) Iris Oifigiúil Achtanna Athbhreithnithe (CAD) (An Coimisiún um Athchóiriú an Dlí) Liosta Rangaithe Reachtaíochta Aistriúcháin (achtanna.
  2. ie)Aistriúcháin (Tithe an Oireachtais) Foilseacháin Rialtais ar Díol Dlí AE (EUR-Lex) CCanna (Ceisteanna Coitianta) Séanadh Aiseolas Deasc chabhrach Cuardach TitleTeideal Year(
  3. s)or rangeBliain nó blianta nó raon TypeCineál All Legislation Acts Statutory Instruments Advanced SearchCuardach Casta HomeBaile Statutory InstrumentsIonstraimí Reachtúla 2025 S.I. No. 229/2025 - Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2025 S.I. No. 229/2025 - Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2025 AmendmentsLeasuithe Download PDF Íoslódáil PDF Notice of the making of this Statutory Instrument was published in “Iris Oifigiúil” of 3rd June, 2025. I, JENNIFER CARROLL MACNEILL, Minister for Health, in exercise of the powers conferred on me by sections 4 and 5 (as amended by section 3 of the Misuse of Drugs (Amendment) Act 2016 (No. 9 of 2016)) of the Misuse of Drugs Act 1977 (No. 12 of 1977), hereby make the following regulations: Citation 1. These Regulations may be cited as the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2025. Definitions 2. In these Regulations – “Principal Regulations” means the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019 ( S.I. No. 262 of 2019 ), as amended by the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2019 ( S.I. No. 583 of 2019 ), the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2019 ( S.I. No. 649 of 2019 ), the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2020 ( S.I. No. 505 of 2020 ), the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2021 ( S.I. No. 557 of 2021 ), the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2022 ( S.I. No. 237 of 2022 ), the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2023 ( S.I. No. 5 of 2023 ) and the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) (No. 2) Regulations 2023 ( S.I. No. 200 of 2023 ). Amending the Principal Regulations 3. The Principal Regulations are amended by substituting for Schedule 1 the following: “SCHEDULE 1 Regulation 2 Specified Controlled Drugs Name of Cannabis product or preparation and brand name Dosage form Concentration of THC (percentage, weight/weight or weight/volume) Name of manufacturer Aurora High CBD Oil Drops Oral solution Less than 3% w/v (<30mg/
  4. ml)This product also contains cannabidiol (CBD) 60% w/v (600mg/
  5. ml)Aurora Cannabis Enterprises Inc., 4439 Township Road 304, Cremona, Alberta, Canada, T0M 0R0 CannEpil ™ Oral solution 0.5% w/v (5mg/
  6. ml)This product also contains cannabidiol (CBD) 10% w/v (100mg/
  7. ml)MGC Pharmaceuticals d.o.o., Kamniška ulica 29, 1000, Ljubljana, Slovenia Tilray Oral Solution THC10:CBD10 (25ml) Oral solution 1% w/v (10mg/
  8. ml)This product also contains cannabidiol (CBD) 1% w/v (10mg/
  9. ml)Tilray Portugal Unipessoal Lda., Zona Industrial de Cantanhede, Lote 121, Cantanhede, 3060-197, Portugal Aurora Sedamen Softgels Capsules 5mg/capsule This product also contains cannabidiol (CBD) less than 0.2mg/capsule Aurora Cannabis Enterprises Inc. 4250 14th Avenue, Markham, Ontario, Canada L3R 0J3 Oleo Bedrobinol Dried flower 13.5% w/w (135mg/
  10. g)This product also contains cannabidiol (CBD) less than 1.0% w/w (less than 10mg/
  11. g)Bureau voor Medicinale Cannabis Postbus 16114 2500 BC DEN HAAG The Netherlands Oleo Bedrocan Dried flower 22% w/w (220mg/
  12. g)This product also contains cannabidiol (CBD) less than 1.0% w/w (less than 10mg/
  13. g)Bureau voor Medicinale Cannabis Postbus 16114 2500 BC DEN HAAG The Netherlands Althea CBD12:THC10 (50ml) Oil 1% w/v THC (10mg/
  14. ml)This product also contains 1.25% w/v (12.5mg/
  15. ml)cannabidiol (CBD) Tasmanian Alkaloids pty Ltd T/A Extractas Bioscience, Westbury, Tasmania, Australia 7303 Oleo Genetics 10:10 Oil (oral solution) 1% w/v (10mg/
  16. ml)This product also contains cannabidiol (CBD) 1% w/v (10mg/
  17. ml)ADREX Pharma GmbH Firmungstrabe 4 56068 Koblenz Germany Oleo Genetics 25:1 Oil (oral solution) 2.5% w/v (25mg/
  18. ml)This product also contains cannabidiol (CBD) <0.1% w/v (<1mg/
  19. ml)ADREX Pharma GmbH Firmungstrabe 4 56068 Koblenz Germany Althea THC20:CBD1 (50ml) Oil 2% w/v THC (20mg/
  20. ml)This product also contains <0.1% w/v (<0.1mg/
  21. ml)cannabidiol (CBD) Tasmanian Alkaloids pty Ltd T/A Extractas Bioscience, Westbury, Tasmania, Australia 7303 Dynabis 25THC:25CBD Oil (oral solution) 2.5% w/v THC (25mg/
  22. ml)This product also contains cannabidiol (CBD) 2.5% w/v (25mg/
  23. ml)NYSK Holdings, Industriska Zona Kjojlija, Patrovec, Skopje MK, 1000, North Macedonia GIVEN under my Official Seal, 29 May, 2025. JENNIFER CARROLL MACNEILL, Minister for Health. EXPLANATORY NOTE (This note is not part of the Instrument and does not purport to be a legal interpretation.) The purpose of these Regulations is to update and replace the current Schedule 1, in the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019 (as amended) (“the Principal Regulations”), in order to include additional cannabis products or preparations for medical use as “specified controlled drugs”. The purpose of the Principal Regulations is to allow additional cannabis products or preparations for medical use to be prescribed and supplied under certain circumstances for the treatment of persons with certain medical conditions under the care of a medical consultant. These Regulations may be cited as the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2025. Privacy Statement Accessibility European Legislation Identifier (PDF) Open Data License Ráiteas Príobháideachais Inrochtaineacht Aitheantóir Eorpach Reachtaíochta (ELI) Ceadúnas Sonraí Oscailte Liosta Fianán © Government of Ireland. Oireachtas Copyright Material is reproduced with the permission of the Houses of the Oireachtas © Rialtas na hÉireann. Atáirgtear ábhar faoi Chóipcheart le cead ó Thithe an Oireachtais

🔗 To official source

AI explanation based on the official legal text. Indicative, not a substitute for legal advice.